Novo Beat Eli Lilly Head-to-Head in weight loss drug showdown
CagriSema cut body weight 12.4% to tirzepatide's 9.1% in a direct phase 3 head-to-head, and Novo's stock fell anyway. The FDA rules on the drug in Q4, with Medicare already paying for the rivals and Lilly $6.5 billion deep in new pill capacity.
Vincent Jiang · 2 min read
Novo has spent the tirzepatide era as the smaller player: 39% of the obesity drug market to Lilly's 60% as of the first quarter 7. At its Capital Markets Day in London on 21 September 2026, Novo announced the answer it has been building.
Lilly's revenue roughly doubled in the tirzepatide era while Novo's stalled
- Eli Lilly
- Novo Nordisk
Data
| Eli Lilly | Novo Nordisk | |
|---|---|---|
| Q3 '24 | $11.4B | $10.5B |
| Q4 '24 | $13.5B | $12B |
| Q1 '25 | $12.7B | $11.3B |
| Q2 '25 | $15.6B | $12.1B |
| Q3 '25 | $17.6B | $11.8B |
| Q4 '25 | $19.3B | $12.4B |
| Q1 '26 | $19.8B | $14.9B |
| Q2 '26 | $23B | $12B |
In REIMAGINE 5, a phase 3 trial putting once-weekly CagriSema 1.0/1.0 mg directly against tirzepatide 5 mg in adults with type 2 diabetes, CagriSema patients lost an estimated 12.4% of body weight at week 60 against 9.1% for tirzepatide, with non-inferior HbA1c reduction, 1.71% to 1.67% 123. In REDEFINE 9, in obesity, CagriSema delivered 21.0% weight loss against 2.0% for placebo 2.
CagriSema beat tirzepatide head-to-head and hit 21% against placebo
- Estimate
Data
| Value | |
|---|---|
| CagriSema 1.0/1.0 mg, obesity (REDEFINE 9) (estimate) | 21% |
| CagriSema 1.0/1.0 mg, diabetes (REIMAGINE 5) (estimate) | 12.4% |
| Tirzepatide 5 mg, diabetes (REIMAGINE 5) (estimate) | 9.1% |
| Placebo, obesity (REDEFINE 9) (estimate) | 2% |
The stock fell anyway
The win did not lift the shares. They fell as much as 9% on Monday as analysts pressed Novo on pricing power and dealmaking ahead of semaglutide patent expiries in the early 2030s 4, extending a year-to-date decline of 21% 5. The fall suggests the market was trading the 2035 target of DKK 150 billion in pipeline sales, about $23 billion, and a CagriSema launch planned for early next year 4, not Monday's numbers.
The comparator was 5 mg, not Lilly's ceiling
The fight inside the data is the dose. REIMAGINE 5 ran tirzepatide at 5 mg; the approved Zepbound and Mounjaro label climbs in 2.5 mg steps to a 15 mg maximum 6. Novo's release anticipates the objection, arguing treatment is individualised and "not all patients receive or remain on the highest available dose" 2.
Every headline figure also rests on the efficacy estimand, per the release's footnote 2. Lilly's strongest dose never entered the ring.
Medicare is paying while Lilly builds
Since 1 July 2026, Medicare's Bridge program has sold obesity GLP-1s to seniors at $50 a month through 2027: Wegovy's pill and injection, Zepbound's KwikPen and Lilly's Foundayo 7. KFF counts 3.8 million eligible seniors, and a Medicare bill of $1.3 billion to $3.3 billion if 10% to 25% of them participate 8.
CagriSema reaches that list only if the FDA approves the December 2025 weight-management filing, a decision due in Q4 2. The day Novo read out, Lilly broke ground on a $6.5 billion Houston plant to make Foundayo 910, a bet The Inference framed as a hedge on a pill shift Novo dominates.
The Q4 verdict is the tell
Watch the FDA decision, then the formularies. If an approved CagriSema lands on public money at a ranked price, Lilly has just poured $6.5 billion into capacity for a race it can now lose on data.
How this brief was made
01Gathered & sourced392 channels · 1,502 articles▾
Agents swept 392 channels and ingested 1,502 articles, then de-duplicated and ranked them for signal.
02Verified & cross-validated12 claims · 37 data feeds▾
Every one of 12 load-bearing claims was checked against primary sources, with 37 live data feeds reconciling the figures and charts.
- 1Investegate, "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial," 21 September 2026
- 2Novo Nordisk via GlobeNewswire, "Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial," 21 September 2026
- 3MPR, "Phase 3 Data Show CagriSema Drives Significant Weight Loss," 21 September 2026
- 4Reuters (Wingrove and Rasmussen) via MSN, "Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says," 21 September 2026
- 5Ad Hoc News, "Novo Nordisk's CagriSema Beats Tirzepatid in Head-to-Head Trial, Yet Shares Slide as London Strategy Day Disappoints," 22 September 2026
- 6Forbes Health, "CagriSema vs. Tirzepatide For Weight Loss: What's the Difference?," 30 June 2026
- 7CNBC, "Medicare will start covering obesity drugs for the first time. Here's what patients should know," 30 June 2026
- 8TechTarget Healthcare Payers, "3.8M qualify for Medicare GLP-1 Bridge at program's July start," 1 July 2026
- 9MT Newswires via Yahoo Finance, "Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site," 21 September 2026
- 10Simply Wall St via Yahoo Finance, "Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?," 22 September 2026
- 11Sharadar quarterly fundamentals, from Eli Lilly's SEC filings, retrieved 24 September 2026
- 12Sharadar quarterly fundamentals, from Novo Nordisk's SEC filings, retrieved 24 September 2026
03Reviewed & edited2 human editors▾
2 editors read the draft against the evidence, tuned the framing, and signed off before it shipped.
Become a contributor
Reporting on the business of AI and want it read? We take pitches from outside contributors who bring primary sources and a number worth arguing about.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
